XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.21.1

Business Segments and Geographic Information | 6 Months Ended
--- | ---
Mar. 27, 2021
Segment Reporting [Abstract] |
Business Segments and Geographic Information | Business Segments and Geographic InformationDuring fiscal 2021, the Company had four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. During fiscal 2020, the Company had five reportable segments that included Medical Aesthetics. The Company completed the sale of its Medical Aesthetics business on December 30, 2019. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 27, 2021 and March 28, 2020. Segment information is as follows:
| Three Months Ended |  | Six Months Ended
| March 27, 2021 |  | March 28, 2020 |  | March 27, 2021 |  | March 28, 2020
Total revenues: |  |  |  |  |  |  |
Diagnostics | $ | 1,064.5 |  |  | $ | 319.2 |  |  | $ | 2,192.7 |  |  | $ | 630.7 |
Breast Health | 336.3 |  |  | 307.8 |  |  | 669.1 |  |  | 638.9 |
GYN Surgical | 114.2 |  |  | 105.4 |  |  | 238.2 |  |  | 224.5 |
Skeletal Health | 22.6 |  |  | 23.7 |  |  | 47.4 |  |  | 47.2 |
Medical Aesthetics | — |  |  | — |  |  | — |  |  | 65.3 |
| $ | 1,537.6 |  |  | $ | 756.1 |  |  | $ | 3,147.4 |  |  | $ | 1,606.6 |
Income from operations: |  |  |  |  |  |  |
Diagnostics | $ | 700.6 |  |  | $ | 57.3 |  |  | $ | 1,485.0 |  |  | $ | 106.8 |
Breast Health | 67.8 |  |  | 75.9 |  |  | 154.1 |  |  | 169.8 |
GYN Surgical | 28.6 |  |  | 23.9 |  |  | 42.3 |  |  | 55.4 |
Skeletal Health | (0.2) |  |  | 1.7 |  |  | 0.8 |  |  | 2.6 |
Medical Aesthetics | — |  |  | (2.4) |  |  | — |  |  | (53.4) |
| $ | 796.8 |  |  | $ | 156.4 |  |  | $ | 1,682.2 |  |  | $ | 281.2 |
Depreciation and amortization: |  |  |  |  |  |  |
Diagnostics | $ | 59.1 |  |  | $ | 59.3 |  |  | $ | 115.4 |  |  | $ | 118.4 |
Breast Health | 12.9 |  |  | 13.1 |  |  | 26.0 |  |  | 23.1 |
GYN Surgical | 23.0 |  |  | 21.1 |  |  | 46.3 |  |  | 42.1 |
Skeletal Health | 0.2 |  |  | 0.2 |  |  | 0.3 |  |  | 0.4 |
Medical Aesthetics | — |  |  | — |  |  | — |  |  | 4.1 |
| $ | 95.2 |  |  | $ | 93.7 |  |  | $ | 188.0 |  |  | $ | 188.1 |
Capital expenditures: |  |  |  |  |  |  |
Diagnostics | $ | 39.3 |  |  | $ | 17.1 |  |  | $ | 77.6 |  |  | $ | 35.3 |
Breast Health | 2.7 |  |  | 8.1 |  |  | 5.6 |  |  | 14.5 |
GYN Surgical | 3.2 |  |  | 5.3 |  |  | 6.5 |  |  | 10.6 |
Skeletal Health | — |  |  | 0.1 |  |  | — |  |  | 0.2 |
Medical Aesthetics | — |  |  | — |  |  | — |  |  | 1.4 |
Corporate | 0.6 |  |  | 1.1 |  |  | 0.9 |  |  | 1.1 |
| $ | 45.8 |  |  | $ | 31.7 |  |  | $ | 90.6 |  |  | $ | 63.1 |
| March 27, 2021 |  | September 26, 2020
Identifiable assets: |  |  |
Diagnostics | $ | 2,584.1 |  |  | $ | 2,161.4 |
Breast Health | 1,266.8 |  |  | 1,200.9 |
GYN Surgical | 1,402.3 |  |  | 1,438.7 |
Skeletal Health | 30.4 |  |  | 38.9 |
Corporate | 2,760.4 |  |  | 2,355.9 |
| $ | 8,044.0 |  |  | $ | 7,195.8 |
The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 27, 2021 and March 28, 2020. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, the United Kingdom and Germany. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows:
| Three Months Ended |  | Six Months Ended
| March 27, 2021 |  | March 28, 2020 |  | March 27, 2021 |  | March 28, 2020
United States | 69.2 | % |  | 76.0 | % |  | 70.0 | % |  | 75.1 | %
Europe | 21.9 | % |  | 14.8 | % |  | 21.4 | % |  | 13.8 | %
Asia-Pacific | 5.9 | % |  | 5.5 | % |  | 5.7 | % |  | 7.0 | %
Rest of World | 3.0 | % |  | 3.7 | % |  | 2.9 | % |  | 4.1 | %
| 100.0 | % |  | 100.0 | % |  | 100.0 | % |  | 100.0 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration